CD8A and neoplasm: Therefore, our data show that only ATRi QDx3 plus RT results in both potentiation of proinflammatory cytokines/chemokines in the tumor to day 7 and promotion of tumor antigen–specific CD8+ T cell expansion in the DLN at day 9.